{
  "ticker": "BOD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972820",
  "id": "02972820",
  "pages": 26,
  "price_sensitive": true,
  "date": "20250725",
  "time": "1540",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m4qcz45c7bpz.pdf",
  "summary": "Here is the concise summary of material information from the ASX announcement:\n\n### **Key Highlights from Appendix 4D (Half-Year Report)**  \n- **Financial Performance**:  \n  - Revenue increased **38%** to **$600,659** (vs. $435,108 pcp).  \n  - Net loss reduced **99.7%** to **$(16,434)** (vs. $(6.14M) pcp).  \n  - Cash balance: **$597,896** (up from $434,401).  \n\n- **Operations**:  \n  - Shift from CBD to THC products drove sales growth (**THC revenue: $380,587**).  \n  - Exited non-core OTC health/beauty segment (no sales vs. $174,514 pcp).  \n  - Gross profit margin: **34%** (vs. 36% pcp).  \n\n- **Deed of Company Arrangement (DOCA) Status**:  \n  - DOCA with Biortica Agrimed remains pending (extension to **7 August 2025**).  \n  - Shareholder EGM expected by **30 September 2025** for approval.  \n  - ASX suspension continues.  \n\n- **Post-Reporting Period Events**:  \n  - Received **$627,279** R&D tax incentive (May 2025).  \n\n- **Capital Structure**:  \n  - Net tangible liabilities: **$(5.45M)** (or **$(3.07)** per share).  \n  - No dividend paid or declared.  \n\n**Material Risks**: Auditor disclaimed conclusion due to uncertainty over DOCA completion and going concern assumptions.  \n\n*Omitted non-material details (director names, routine disclosures).*",
  "usage": {
    "prompt_tokens": 13044,
    "completion_tokens": 359,
    "total_tokens": 13403,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-25T05:52:09.825653"
}